Barclays raised the firm’s price target on Abbott (ABT) to $158 from $149 and keeps an Overweight rating on the shares. The firm increased earnings estimates for Abbott’s 2025, “despite significant headwinds” from currency and taxes. It continues to view the company as a “high-quality diversified MedTech growth story.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Abbott price target raised to $135 from $130 at Stifel
- Abbott price target raised to $138 from $135 at Bernstein
- Abbott price target raised to $148 from $146 at UBS, shares remain undervalued
- Abbott Laboratories Reports Strong 2024 Financial Results
- Abbott price target raised to $140 from $139 at BTIG